LIFE logo

Lifecare ASA Stock Price

OB:LIFE Community·NOK 86.9m Market Cap
  • 1 Narratives written by author
  • 1 Comments on narratives written by author
  • 2 Fair Values set on narratives written by author

LIFE Share Price Performance

NOK 0.29
-5.27 (-94.76%)
NOK 0.40
Fair Value
NOK 0.29
-5.27 (-94.76%)
27.1% undervalued intrinsic discount
NOK 0.40
Fair Value
Price NOK 0.29
AnalystConsensusTarget NOK 0.40

LIFE Community Narratives

·
Fair Value NOK 0.4 27.1% undervalued intrinsic discount

TTP Collaboration And Sensor Chemistry Will Streamline Manufacturing

0users have liked this narrative
1users have commented on this narrative
0users have followed this narrative

Trending Discussion

Updated Narratives

LIFE logo

LIFE: Long Term Margins And Lower Risk Will Drive Future Repricing

Fair Value: NOK 0.4 27.1% undervalued intrinsic discount
0 users have set this as their fair value
1 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Medium-low risk with mediocre balance sheet.

6 Risks
1 Reward

Lifecare ASA Key Details

NOK 7.4m

Revenue

NOK 0

Cost of Revenue

NOK 7.4m

Gross Profit

NOK 143.5m

Other Expenses

-NOK 136.1m

Earnings

Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
Aug 19, 2026
-0.46
100.00%
-1,835.15%
0%
View Full Analysis

About LIFE

Founded
2006
Employees
25
CEO
Joacim Holter
WebsiteView website
lifecare.no

Lifecare ASA, together with its subsidiaries, operates as a medical sensor company that develops technology for sensing and monitoring of various body analytes in Norway. The company develops Sencell, a 3D printed nano-sensor for monitoring glucose levels in patients with diabetes and for veterinary applications; as well as medical devices that remove subdermal implants. Lifecare ASA was founded in 2006 and is headquartered in Bergen, Norway.

Recent LIFE News & Updates

Narrative Update Jun 23

LIFE: Long Term Margins And Lower Risk Will Drive Future Repricing

The analyst price target for Lifecare has been revised higher by NOK 6, with analysts citing slightly lower required returns and refined long-term P/E and margin assumptions as the main drivers of the change. Analyst Commentary Recent commentary on Lifecare focuses on how updated price targets and valuation frameworks line up with the company’s long term earnings and margin potential, as well as the execution risks that could affect those outcomes.

Recent updates

No updates